Follow-up of ARCHES Trial Shows Extended Survival
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxFinal Data From Phase 3 PSMAfore Trial About 177Lu-PSMA-617 (Pluvicto)
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxNew Phase 3 Trial Approved for Masitinib for mCRPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxMevrometostat Update: a New Phase 3 Trial for mCSPC
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 Trial: Ifinatamab Deruxtecan (MK-2400) for metastatic Castration-Resistant Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxAMPLITUDE Trial Update: Niraparib Plus Abiraterone Shows Promise for HRR-Altered Metastatic Prostate Cancer
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxTALAPRO-2 Trial: Final Results Update For HRR Mutations (BRCA, ATM,…)
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxPhase 3 ENZAMET Trial: Follow-up Data After 8 Years
/0 Comments/in Clinical Trial, Metastatic, Phase 3/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
225Ac abiraterone acetate ADC AI ai in healthcare alphafold antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial clinical trials crispr darolutamide drug repurposing drug resistance enzalutamide HRR immunotherapy mcrpc metastatic castration-resistant prostate cancer metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer olaparib oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STAMPEDE trial theranostics
Latest Posts
- Newsletter 37/2025 September 14, 2025
- OST-504: A Novel Immunotherapy Targeting Prostate Cancer September 13, 2025
- Memantine Shows Promise Against Advanced Prostate Cancer September 11, 2025
- Pasritamig in Late-Line Prostate Cancer: From Early Findings to the KLK2-comPAS Trial September 11, 2025